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Highlights 
 
 Clinical outcomes are excellent using an alemtuzumab-containing HSCT regimen for aplastic 
anemia 
 
 Outcomes are excellent despite prolonged abnormality of the T-cell profile 
 
 Recipient-derived CD8 T cells shape persistent mixed chimerism 
 
Abstract 
Prevention of graft versus host disease (GVHD) is paramount for allogeneic 
hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases. We 
previously reported that allogeneic HSCT for severe aplastic anemia (SAA) using the 
fludarabine, cyclophosphamide and alemtuzumab (‘Campath’) (FCC) regimen is 
associated with very low risk of GVHD and excellent clinical outcomes. We now 
report a single center study of 45 patients with longer follow up and investigation of 
lymphocyte recovery. Overall survival (OS) was 93% and event-free survival (EFS) 
90.7%. Acute and chronic GVHD occurred in 6 (13.3%) patients, respectively, and 
only one case was severe. Mixed T-cell chimerism was frequent and persisted after 
cessation of post graft immunosuppression. T cells were extensively depleted 
comprising only 11.3% of lymphocytes at day 30 rising to 43.8% by one year, but still 
significantly below normal (67.2%, P=0.018) and deficiency persisted after 
immunosuppressive therapy withdrawal. Depletion of CD4 T cells was particularly 
profound causing inversion of the normal CD4 to CD8 T-cell ratio.  T-cell subset 
composition was also abnormal, with memory and effector T cells predominate for at 
least six months after FCC HSCT. Analysis of T-cell subset chimerism showed CD4 
T cells were predominantly donor-derived at one year whereas recipient-derived CD8 
T cells shaped mixed chimerism with notable contribution of recipient effector CD8 T 
cells. Prolonged mixed T-cell chimerism after withdrawal of post graft 
immunosuppression and low incidence of GVHD indicates mutual tolerance is 
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established, but incidence of viral disease was low suggesting that anti-viral immunity 
is maintained. The study showed that despite abnormality of the T-cell profile after 
allogeneic HSCT for SAA using the FCC regimen, it is conducive for excellent 
clinical outcome. 
 
Introduction 
 
In contrast to hematologic malignancies where GVHD has an important graft versus 
leukemic effect, there is no advantage for any GVHD in allogeneic HSCT for non-
malignant diseases. In vivo T-cell depletion (TCD) is used to reduce GVHD. We 
pioneered the use of alemtuzumab instead of antithymocyte globulin (ATG) for 
allogeneic HSCT with TCD to treat SAA. Using the ‘FCC’ conditioning regimen of 
fludarabine, low dose cyclophosphamide with alemtuzumab (‘Campath-1H’), we 
previously reported in a retrospective multi-center study an OS of 85-90% and a 
remarkably low incidence of chronic GVHD 1 2. Subsequent studies have confirmed 
the benefit of alemtuzumab over ATG in reducing both acute and chronic GVHD in 
SAA HSCT 3 4 5. A recent large multicenter study examining cyclophosphamide dose 
de-escalation in unrelated donor HSCT for SAA using ATG, confirmed excellent OS 
but the 1-year incidence of chronic GVHD was 22.5-31.7%, depending on 
cyclophosphamide dose used 6. Allogeneic HSCT with alemtuzumab for TCD has 
also been applied to the treatment of sickle cell anemia and excellent clinical 
outcomes reported 7.   
 
Previous studies of chimerism post HSCT for SAA examining unfractionated blood 
mononuclear cells have demonstrated a significant incidence of mixed chimerism. 
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Although graft failure occurred in a high proportion of patient with progressive mixed 
chimerism, stable mixed chimerism was associated with a low risk of chronic GVHD 
8. Among FCC HSCT patients, we observed that stable mixed T-cell chimerism 
alongside full donor myeloid engraftment is frequent and persists after cessation of 
post graft immunosuppression 1. This has also been reported in a proportion of 
children transplanted for SAA using FCC regimen 9. The very low incidence of 
GVHD and sustained mixed T-cell chimerism suggests that a state of mutual 
immunological tolerance exists after FCC HSCT. In this study, we have investigated 
the recovery of lymphocyte subsets in SAA patients transplanted at King’s College 
Hospital using the FCC-conditioning regimen. We report the lymphocyte profile 
associated with excellent clinical outcomes and the basis for persistent co-existence of 
donor and recipient T cells.  
 
Methods 
Patients 
From 2007 to 2015, 45 consecutive patients with acquired idiopathic SAA were 
transplanted at King’s College Hospital. The diagnosis of AA 10 and the disease 
severity 11 12 was defined using standard criteria. Fanconi anemia was excluded by 
diepoxybutane stimulation of cultured peripheral blood chromosomes. Patients with 
likely constitutional AA, based on an identified mutation, family history, and/or 
somatic anomalies but no identified mutation, were excluded. Patient characteristics 
are summarized in Table 1. National Research Ethics Committee approval was 
obtained to collect patient samples for research studies via the King’s College London 
Haemato-Oncology Tissue Bank, and informed written consent was obtained in 
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accordance with the Declaration of Helsinki.  
 
Transplant conditioning regimen 
High resolution DNA typing for HLA-A, B, C, DRB1 and DQB1 was performed for 
all patients. The FCC conditioning regimen was used for 10/10 HLA-matched HSCT 
patients, as previously described 1. FCC conditioning with 2Gy total body irradiation 
was used for 9/10 HLA-matched HSCT patients. Median alemtuzumab dose was 
70mg (range 45-100). Cyclosporine (CSA) alone was used as post HSCT IST. Four 
patients later required addition of mycophenolate mofetil due to renal impairment that 
precluded full dose CSA. Target trough CSA blood levels were 250-350 mcg/l. IST 
was continued for 9 months post HSCT, followed by tapering over the subsequent 3 
months, provided hematologic parameters and mixed T-cell chimerism were stable.  
 
 
Lymphocyte phenotyping 
Twenty-nine patients underwent longitudinal multi-parameter flow cytometric 
analysis of lymphocyte subset reconstitution. Patients who had prednisolone or 
rituximab were excluded after treatment commenced. Analysis of 11 adult healthy 
volunteers was also performed. Cryopreserved peripheral blood mononuclear cells 
were thawed and labeled with fluorochrome conjugated antibodies to characterize 
lymphocyte subsets. Analysis was performed by flow cytometry using a BD 
FACSCanto II or a BD LSRFortessa. Results were analyzed with FlowJo software. 
Dead cells were excluded from the analysis based on their forward- and side-light 
scatter properties and use of a Zombie Fixable dead cell staining kit (Biolegend). 
Monocytes were excluded based on expression of CD14. NK cells were defined as 
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CD3-/CD19-/CD56+. B cells were defined as CD19+. CD4 T cells were defined as 
CD3+/CD4+ and CD8 T cells as (CD3+/CD8+) with naïve 
(CD45RA+/CD27+/CD62L+), memory (CD45RA-/CD27+), effector (CD45RA-
/CD27-/CD62L-) and terminal effector (CD45RA+/CD27-/CD62L-) subsets.  
 
Chimerism  
Chimerism was assessed in unfractionated peripheral blood, CD3+ T cells and CD15+ 
granulocytes. Full donor chimerism was defined as > 95% donor hematopoietic cells. 
Lymphocyte subsets were isolated using a BD FACSAria II cell sorter (purity >95%). 
Genomic DNA was extracted using a QIAamp DNA Micro kit (Qiagen). Percentage 
donor chimerism was determined using the PowerPlex 16 HS (Promega) multiplex 
short tandem repeat system for DNA typing. Genetic analysis was performed using an 
Applied Biosystems 3130xl and results interpreted using ChimerMarker (Version 
3.0.9).  
Statistical analysis  
Univariate comparisons and multivariate analysis was performed using the Cox 
proportional hazards regression model with Statistical Package for the Social Science 
(SPPS) software. Comparisons of lymphocyte subset composition in patients and 
healthy volunteers were made with the Mann-Whitney U test using GraphPad Inc. 
software, Prism version 6.0. All tests were 2-tailed, with P-values <0.05 considered to 
be statistically significant. All data were censored as of 30 December 2015. 
 
 
Results 
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Clinical outcomes after FCC HSCT 
In this single center study, we have confirmed the excellent clinical outcomes as 
previously reported following HSCT using FCC conditioning for SAA 1 (Table 2). 
The median patient follow-up after HSCT was 31.4 months (range 3-93) with 
excellent OS and event-free survival (EFS) at five years of 93 and 91% respectively. 
Importantly there was no significant difference in outcomes for MSD compared to 
UD transplants or for patients aged > 50 years (n=14), compared to younger patients. 
Three patients died, resulting in a TRM rate of 7% at one year. The rate of GVHD 
was very low; the majority of which was mild. Reliable and sustained engraftment 
was observed with only one graft failure noted in a patient who received a suboptimal 
bone marrow infusion cell dose. Sequential chimerism data were available for 42 
(93%) patients that confirmed the persistent mixed T-cell chimerism previously 
reported with the FCC conditioning regimen 1 (Figure 1A).  
 
Epstein-Barr virus (EBV) viremia was detected in 20 (47%) patients, but treatment 
was only required in two (5%) patients. One patient developed biopsy-proven EBV 
post-transplant lymphoproliferative disease (PTLD) on day 120 and the second had 
excessive EBV viral load on day 66 but no signs of PTLD; Cytomegalovirus (CMV) 
viremia was observed in 11 (42%) patients, but no patients progressed to CMV 
disease due to pre-emptive therapy. Adenovirus viremia was observed in 3 (7%) 
patients. Invasive fungal infections were diagnosed in three (7%) patients, two with a 
fatal outcome who both had the infection pre-transplant. 
 
Post FCC HSCT, 9 patients (20%) developed autoimmune-like pathologies; 4 with 
hemolytic anemia, 4 with pure red cell aplasia, (1 of whom also had immune 
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thrombocytopenia and 1 who had thyroiditis) and 1 with probable immune-mediated 
neutropenia that responded to granulocyte colony stimulating factor (supplementary 
Table 1. All 4 cases of pathology classified as warm type autoimmune hemolytic 
anemia (AIHA) responded to prednisolone but 3 relapsed, 2 of 2 responded to 
rituximab. The other patient, who received a 9/10 HLA-match HSCT, had refractory 
and fulminant hemolysis in association with severe GVHD and multiple thromboses. 
Of the 4 cases of pure red cell aplasia (PRCA), 3 received a major ABO mis-matched 
transplant that is the likely cause of their PRCA. Three of four patients recovered 
attaining transfusion independence while in one patient the PRCA was refractory to 
steroids, intravenous immunoglobulin, rituximab, and donor lymphocyte infusion. 
This patient has received a second HSCT from an alternative ABO matched MUD.  
 
Lymphocyte reconstitution after FCC HSCT 
Serial analysis of peripheral blood lymphocytes of 29 patients after FCC HSCT 
showed the expected lymphopenia associated with use of alemtuzumab, and total 
number of lymphocytes remained significantly below normal (P<0.0001) at one year 
and beyond (Figure 1B). NK cells were the predominant lymphocyte population 
present early post HSCT comprising 49.3% of lymphocytes at day 30 (Figure 1C). B 
cells were not detected at day 30, but rapidly recovered comprising 31.7 of 
lymphocytes at day 60  (Figure 1C) and frequency remained significantly above 
normal at day 360 (23.7% compared to 10.5% for healthy volunteers, P=0.002%).  
 
T-cell deficiency is prolonged and the CD8 T-cell population is skewed to an 
effector phenotype 
T cells were profoundly deficient, comprising only 11.3% of lymphocytes at day 30, 
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increasing to 43.8% at one year, but still significantly below normal (67.2%, 
P=0.018) (Figure 1C). Rapid recovery of B cells with prolonged T-cell deficiency 
produced abnormal dominance of B cells over T cells, maintained long term. 
Frequencies of CD4 T cells within the T-cell population were lower than normal 
producing inversion of the usual CD4 to CD8 T-cell ratio (Figure 1D). Memory and 
effector T cells predominated early post HSCT (Figure 1E). Naïve T cells began to 
recover from 6 months (Figure 1E). Composition of naïve, memory and effector 
subsets within the CD4 T-cell population were near normal at one year (Figure 1E left 
panel). In contrast, CD8 T-cell subset composition remained abnormal at one year due 
to a high proportion of effector T cells (57.2% compared to 9.3% for healthy 
volunteers, P<0.0001) (Figure 1E right panel).  
 
Persistence of recipient CD8 T cells after FCC HSCT  
Lymphocyte subsets from five patients that were mixed T-cell chimeric at one year 
were isolated by fluorescence-activated cell sorting, and donor / recipient composition 
determined by analysis of informative alleles from polymorphic short tandem repeat 
loci. Four patients were > 93% donor NK cells and >76% donor B cells. Patient 3 was 
only 39% donor NK cells and 76% donor B cells. Naïve, memory and effector T-cell 
subsets were isolated using the gating strategy shown Figure 2A. Results shown in 
Figure 2B revealed that mixed T-cell chimerism at one year was principally due to 
persistence of recipient CD8 T cells. Median percentage contribution to recipient CD3 
chimerism was 37.9% for the CD8 T-cell population and 8.5% for the CD4 T-cell 
population (P=0.008). Recipient chimerism was detected in all CD8 T-cell subsets, 
but with notable contribution of the effector subset in patients 3 and 4 who both had 
CMV reactivation early after HSCT. A significant correlation was observed between 
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lower donor T-cell chimerism at day 360 and CMV reactivation or EBV viraemia 
early after HSCT. Patients that were donor and/or recipient CMV/EBV seropositive 
but had no viraemia post HSCT were median 77% donor CD3 compared to median 
57% donor CD3 for patients that had viraemia post HSCT (P=0.036). Follow-up 
analysis of patients 1, 2 and 3 at >2 years post HSCT showed that the T-cell subset 
mixed chimerism profile remained stable after IST cessation and numbers of CD4 and 
CD8 T cells did not increase (data not shown).  
 
 
Discussion 
Using the FCC conditioning regimen for allogeneic HSCT to treat SAA at a single 
center and with long-term follow up, we confirm the excellent clinical outcomes 
previously reported in our multi-center study 5. Incidence of chronic GVHD was 
remarkably low, particularly given the high proportion of MUD in this cohort. The 
comparable outcome of older (>50 years of age) and younger patients is also 
encouraging, given that increasing age is typically associated with worse outcome 13. 
Rapid full donor myeloid engraftment occurred and there was only one case of graft 
failure, associated with low infused bone marrow stem cell dose.  The majority of 
patients exhibited sustained mixed T-cell chimerism that persisted despite withdrawal 
of immunosuppression at one year after transplantation.  
 
The alemtuzumab-containing FCC regimen caused profound and prolonged T-cell 
depletion, particularly CD4 T cells that recovered more slowly than CD8 T cells. The 
small numbers of T cells that survived depletion with alemtuzumab were almost 
exclusively of the memory or effector subsets and dominated the circulating 
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population for at least six months. We previously reported the same selective 
preservation of antigen-experienced T cells after HSCT using a fludarabine, 
busulphan with alemtuzumab regimen for treatment of patients with hematological 
malignancies 14. The very slow recovery of T cells is likely due to thymic atrophy in 
adults limiting de novo production of naïve T cells after HSCT. The combination of 
T-cell depletion and the relatively mild conditioning with fludarabine and low dose 
cyclophosphamide that is unlikely to induce a strong cytokine storm limits potential 
for T-cell alloreactivity. Of the seven patients who developed GVHD, six were >90% 
donor CD3 and one was 75% donor CD3 by day 60.  
 
Mixed T-cell chimerism is frequent after reduced intensity conditioning and 
particularly common after TCD with alemtuzumab 15. Our investigation of mixed 
chimerism within T-cell subsets found that CD4 T cells were mainly donor-derived 
by one year but CD8 T cells remained predominantly recipient-derived. Although 
naïve, memory and effector subset frequencies in the CD4 T-cell population were 
near normal by one year, numbers were low in all patients and deficiency persisted 
after cessation of IST. In contrast, recovery of CD8 T cells was much more robust, 
but an atypical composition developed due to expansion of the effector CD8 T-cell 
subset that rose from a mean of 17.6% CD8 T cells at day 90 to 57.2% at one year 
(compared to 9.3% for healthy volunteers). Recipient cells were present in all CD8 T-
cell subsets, but was notably high in the effector population and particularly for the 
two patients who had CMV reactivation early after HSCT.  
 
Expansion of the effector CD8 T-cell population occurred despite continued IST for 
at least one year. CMV reactivation and EBV viremia early after transplantation 
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correlated with higher recipient CD3 chimerism at one year and we therefore 
speculate that expansion of effector CD8 T cell numbers may be due to antigen-driven 
proliferation of pathogen-specific recipient CD8 T cells. Limited sample availability 
and low T-cell numbers precluded our investigation of the antigen-specificity of the 
effector CD8 T cells. The incidence of viral disease post FCC was low, despite EBV 
and CMV viremia in 47% and 42% of patients respectively. Recipient-derived 
effector CD8 T cells may confer a degree of anti-virus immunity after FCC HSCT, 
despite continued IST. Other studies have recently reported that virus-specific CD8 T 
cells can have a substantial impact on T-cell composition after HSCT. Massive 
expansion of CMV-specific effector CD8 T cells is seen following CMV reactivation 
after HSCT and has a long-term impact on T-cell reconstitution 16 17. In the setting of 
TCD using alemtuzumab-based reduced intensity conditioning in patients 
transplanted for hematologic malignancies, Sellar and colleagues showed that CMV-
specific CD8 T cells were of recipient origin and contributed significantly to higher 
recipient chimerism 18.   
 
For patients with hematological malignancies, routine clinical practice is to administer 
donor lymphocyte infusions (DLI) for mixed T-cell chimerism to promote conversion 
to full donor chimerism and prevent disease relapse 19. DLI is not administered to 
SAA patients after FCC HSCT because disease relapse does not occur and DLI has 
the associated risk of GVHD.  Our study of lymphocyte composition and chimerism 
has provided novel insight into the long-term impact of HSCT conditioning with 
alemtuzumab. Stable co-existence of donor and recipient T cells for many years after 
withdrawal of immunosuppression, reliable engraftment and low rates of GVHD 
indicates that a state of mutual tolerance exists after allogeneic FCC HSCT. HLA-
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matching, T-cell depletion using alemtuzumab together with IST for at least one year 
after HSCT is an effective strategy to minimize alloreactivity. Although our study 
showed the FCC HSCT regimen results in an atypical lymphocyte composition, 
clinical course and outcomes for patients are remarkably good.  
 
The only complication consistently observed after FCC HSCT is emergence of 
autoimmune-like diseases that are predominantly antibody-mediated cytopenias, seen 
in 6 (14%) patients in this study. Secondary autoimmune disorders commonly occur 
after treatment with alemtuzumab in other clinical settings 20. Prolonged T-cell 
deficiency may contribute to dysregulated B-cell behavior. We have previously 
reported that clonal gammopathies are frequent after using alemtuzumab-based HSCT 
21. No association of autoimmune-like disease with circulating B cells or other 
lymphocyte populations was found in our study (data not shown).  
 
In conclusion, despite persistent T-cell deficiency, excellent survival and low 
incidence of viral disease was observed after FCC HSCT for SAA. The very low 
incidence of GVHD with long-term stable mixed T-cell chimerism, shaped by 
recipient CD8 T cells, in the absence of immunosuppression indicates that FCC 
conditioning favors mutual tolerance.  
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Figure Legends 
 
Figure 1. Serial analysis of peripheral blood chimerism and lymphocyte 
composition after FCC HSCT. (A) Percentage donor chimerism of unfractionated, 
purified CD3 and purified CD15 peripheral blood cells. Mean and SEM are shown. 
(B) Reconstitution of peripheral blood lymphocytes after FCC HSCT. Median and 
interquartile range are shown and the horizontal dotted lines enclosing grey boxes 
represent the median and interquartile range of 11 adult healthy volunteers. 
Comparisons between cell numbers at each time point and healthy volunteers were 
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performed using a 2-tailed Mann-Whitney U test.  Lymphocyte numbers at all time 
points were significantly below numbers for healthy volunteers (P <0.0005). (C) 
Percentage of NK, B and T cells. Mean and SEM are shown and values for 11 adult 
healthy volunteers (HV) indicated. (D) Percentage of CD4 and CD8 T cells within the 
CD3 T-cell population using mean values. (E) Percentage naïve, memory and effector 
subset composition of CD4 T cells (left panel) and CD8 T cells (right panel). Mean 
and SEM are shown and values for 11 adult healthy volunteers (HV) indicated. 
 
Figure 2. Analysis of individual patients showed sustained mixed T-cell 
chimerism at after FCC HSCT is primarily due to persistence of recipient CD8 T 
cells, with notable contribution of the effector subset. (A) Panels illustrate the 
gating strategy used for isolation of naïve, memory and effector T-cell subsets by 
FACS. (B) CD4 T-cell (left panel) and CD8 T-cell (right panel) subset chimerism at 
one year for five patients. CMV serostatus donor/recipient and reactivation early post 
HSCT: Patient 1 negative/negative, Patient 2 negative/positive no reactivation, Patient 
3 positive/negative and reactivation, Patient 4 negative/positive and reactivation, 
Patient 5 negative/positive no reactivation.  
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Figure 2 
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Table 1: Patient pre-transplant characteristics 
Number of patients 45 
Median age (range) 
Number of patients aged > 50yr 
32 (15 – 63) 
14 (31.1%) 
Male / Female 28 / 17 
Etiology of aplasia 
 Idiopathic 
 Post-hepatitic (seronegative) 
 Eosinophilic fasciitis 
 Coeliac disease 
 
41 (91.2%) 
2 (4.4%) 
1 (2.2%) 
1 (2.2%) 
Type of donor 
 Matched sibling (MSD) 
 Unrelated donor (UD) 
 9/10 UD 
 
12 (26.6%) 
33 (73.4%) 
8 of 33 (24.2% of UD) 
Previous immunosuppressive therapy 
 MSD  
 UD  
 
 
6 of 12 (50%) 
27 of 33 (81.8%) p = 0.055 
 
Median time to transplant 
 MSD  
 UD   
 
5.9 (2.7-34.7) 
8.4 (2.1-178.9) p = 0.095 
 
Number of patients HLA alloimmunised 11 (24.4%) 
Stem cell source 
 Bone marrow 
 Peripheral blood stem cells 
 
7 (15.5%) 
38 (84.5%) 
Number of patients with PNH clone 
Median PNH clone size: 
 Granulocytes 
 Monocytes 
 Red cells 
21 (46.6%) 
 
2% (range 0.02 – 40) 
2.85% (range 0.01 – 32) 
Not Available in the table 
Median alemtuzumab dose 70 mg (Range 45 – 100) 
Median CD34+ stem cell dose 6.55x106 CD34+/Kg 
(Range 1.97 – 12.40) 
Median follow up after HSCT 31.4 months (Range 3 – 93) 
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Table 2. Patient outcomes after FCC HSCT 
Median time to neutrophil count > 0.5 x 109/l 12 days (Range 10 – 22) 
Median time to platelets > 20 x 109/l 12 days (Range 9 – 61) 
Primary graft failure 1 (2.2%) 
Acute GVHD: 
 Grade I/II 
 Grade III/IV 
6 (13.3%) 
 6 of 6 (100%) 
 0 of 6 
Chronic GVHD: 
 Mild 
 Moderate 
 Severe 
6 (13.3%) 
 4 of 6 (66%) 
 1 of 6 (17%) 
 1 of 6 (17%) 
1-year TRM 3 (6.6%) 
5-year OS 93.1% 
5-year EFS 90.7% 
5-year EFS MSD (n=12) vs UD (n=33) 100% vs 87.4% (P=0.219) 
5-year EFS Age ≤ 50 years (n=31) vs >50 years (n=14) 93% vs 85.7% (P=0.356) 
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